The company had a total of 14,287 patient treatments, up 14 per cent on FY13 and achieved a pregnancy success rate of 32 per cent. Monash shares climbed 1. 9 per cent to $1. 66 as of 11. 25am, but have dropped about 10 per cent from its issue price of $1. 85 since its debut.
The pro-forma net profit after tax result was $22. 6 million for the year ending June 30, which was 2. 7 per cent higher than its prospectus forecast and a 23 per cent jump on the previous year.
Monash IVF has attributed pregnancy success rates for beating the full-year profit that was forecast in the IPO prospectus and says it is on track to achieve its goals set out for 2015.
Alan has been a trusted source of investment advice to Australians for many years, and in 2005 he founded Eureka Report - Australia’s #1 online investment report.
Read more here: Business Spectator